TY  - GEN
AU  - Ritchie,Ryan
AU  - Barrett,Michael
AU  - Mottram,Jeremy
AU  - Myburgh,Elmarie
TI  - Chapter 48 In Vivo Bioluminescence Imaging to Assess Compound Efficacy Against Trypanosoma brucei
SN  - 978-1-0716-0294-2_48
PY  - 2020///
PB  - Springer Nature
KW  - Biology, life sciences
KW  - bicssc
KW  - Firefly luciferase, Trypanosoma brucei brucei, In vivo imaging, Bioluminescence
N1  - Open Access
N2  - Traditional animal models for human African trypanosomiasis rely on detecting Trypanosoma brucei brucei  parasitemia in the blood. Testing the efficacy of new compounds in these models is cumbersome because it  may take several months after treatment before surviving parasites become detectable in the blood. To  expedite compound screening, we have used a Trypanosoma brucei brucei GVR35 strain expressing  red-shifted firefly luciferase to monitor parasite distribution in infected mice through noninvasive wholebody  bioluminescence imaging. This protocol describes the infection and in vivo bioluminescence imaging  of mice to assess compound efficacy against T. brucei during the two characteristic stages of disease, the  hemolymphatic phase (stage 1) and the encephalitic or central nervous system phase (stage 2)
UR  - https://library.oapen.org/bitstream/20.500.12657/47835/1/Bookshelf_NBK558235.pdf
UR  - https://directory.doabooks.org/handle/20.500.12854/64619
ER  -